OBJECTIVE: To determine the diagnostic accuracy of WB-MRI and 18F-FDG PET/CT in detecting infiltration pattern, disease activity, and response to treatment in patients with multiple myeloma (MM). MATERIALS AND METHODS: Fifty-six patients with confirmed MM were included in the present study for pre-treatment evaluation. Among these individuals, 22 patients were available for the post-treatment evaluation of response to therapy. All patients were imaged with both WB-MRI and 18F-FDG PET/CT. All radiographic findings of infiltration pattern, disease activity, and response to therapy were compared. The diagnostic performance of both modalities was estimated using bone marrow aspirate and biopsy as the reference test. RESULTS: For detection of active myelomatous tissue at diagnosis, WB-MRI achieved higher sensitivity (94%) than 18F-FDG PET/CT (75%) (p = 0.0039), whereas both modalities achieved the same specificity (80%). For detection of residual myelomatous tissue after treatment, 18F-FDG PET/CT achieved higher specificity (86%) than WB-MRI (43%) (p = 0.0081), whereas both modalities achieved the same sensitivity (75%). CONCLUSION: WB-MRI is more sensitive than 18F-FDG PET/CT in the diagnosis of MM before treatment; however, 18F-FDG PET/CT is more specific than WB-MRI in detecting residual involvement in treated patients.
OBJECTIVE: To determine the diagnostic accuracy of WB-MRI and 18F-FDG PET/CT in detecting infiltration pattern, disease activity, and response to treatment in patients with multiple myeloma (MM). MATERIALS AND METHODS: Fifty-six patients with confirmed MM were included in the present study for pre-treatment evaluation. Among these individuals, 22 patients were available for the post-treatment evaluation of response to therapy. All patients were imaged with both WB-MRI and 18F-FDG PET/CT. All radiographic findings of infiltration pattern, disease activity, and response to therapy were compared. The diagnostic performance of both modalities was estimated using bone marrow aspirate and biopsy as the reference test. RESULTS: For detection of active myelomatous tissue at diagnosis, WB-MRI achieved higher sensitivity (94%) than 18F-FDG PET/CT (75%) (p = 0.0039), whereas both modalities achieved the same specificity (80%). For detection of residual myelomatous tissue after treatment, 18F-FDG PET/CT achieved higher specificity (86%) than WB-MRI (43%) (p = 0.0081), whereas both modalities achieved the same sensitivity (75%). CONCLUSION: WB-MRI is more sensitive than 18F-FDG PET/CT in the diagnosis of MM before treatment; however, 18F-FDG PET/CT is more specific than WB-MRI in detecting residual involvement in treated patients.
Entities:
Keywords:
18F-FDG PET/CT; Before and after treatment; Multiple myeloma; WB-MRI
Authors: L A Moulopoulos; D Gika; A Anagnostopoulos; K Delasalle; D Weber; R Alexanian; M A Dimopoulos Journal: Ann Oncol Date: 2005-08-08 Impact factor: 32.976
Authors: S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel Journal: Blood Date: 2011-02-03 Impact factor: 22.113
Authors: Ho Young Park; Kyung Won Kim; Min A Yoon; Min Hee Lee; Eun Jin Chae; Jeong Hyun Lee; Hye Won Chung; Dok Hyun Yoon Journal: Cancer Imaging Date: 2020-01-30 Impact factor: 3.909
Authors: Olwen Westerland; Ashik Amlani; Christian Kelly-Morland; Michal Fraczek; Katherine Bailey; Mary Gleeson; Inas El-Najjar; Matthew Streetly; Paul Bassett; Gary J R Cook; Vicky Goh Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-19 Impact factor: 9.236
Authors: Maria E S Takahashi; Camila Mosci; Edna M Souza; Sérgio Q Brunetto; Elba Etchebehere; Allan O Santos; Mariana R Camacho; Eliana Miranda; Mariana C L Lima; Barbara J Amorim; Carmino de Souza; Fernando V Pericole; Irene Lorand-Metze; Celso D Ramos Journal: Sci Rep Date: 2019-11-11 Impact factor: 4.379